Singapore markets closed

ICL Group Ltd (ICL.TA)

Tel Aviv - Tel Aviv Delayed price. Currency in ILA (0.01 ILS)
Add to watchlist
1,768.00-37.00 (-2.05%)
As of 02:07PM IDT. Market open.
Full screen
Previous close1,805.00
Open1,780.00
Bid1,768.00 x 20100
Ask1,773.00 x 1591600
Day's range1,765.00 - 1,796.00
52-week range1,629.00 - 2,480.00
Volume1,379,464
Avg. volume1,927,559
Market cap22.799B
Beta (5Y monthly)0.59
PE ratio (TTM)9.40
EPS (TTM)1.88
Earnings date09 May 2024
Forward dividend & yield0.70 (3.86%)
Ex-dividend date14 Mar 2024
1y target est5.29
  • Business Wire

    ICL Announces First Quarter 2024 Earnings Call

    TEL AVIV, Israel, April 15, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced it plans to release first quarter 2024 results prior to the opening of the TASE market on Thursday, May 9, 2024.

  • Business Wire

    ICL Files 2023 Annual Report on Form 20-F

    TEL AVIV, Israel, March 14, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (SEC). Included, for the third year in a row, are Task Force on Climate-related Financial Disclosures (TCFD), which provide information on what ICL is doing to mitigate the risks of climate change and reduce its carbon footprint.

  • Business Wire

    ICL Accelerating Biologicals Portfolio Growth in Brazil with Strategic Acquisition

    TEL AVIV, Israel, February 28, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced it has acquired Nitro 1000, a manufacturer, developer and provider of biologicals in Brazil for approximately $30 million. This acquisition marks another meaningful step into the biologicals market, while expanding ICL’s product offerings and positioning the company for further expansions into new and adjacent end-markets.